MGI Australia Unveils Its CEC with DCS Lab Products Featuring Pioneering Technology in DNA, Cell, and Spatial-omics Technology

Australia first market outside China to access revolutionary new capability

BRISBANE, AUSTRALIA, 13^th Dec 2023 - MGI Australia, a subsidiary of MGI Tech Co. Ltd. (MGI), a global leader in life science technology, is delighted to announce a substantial expansion of its Brisbane Customer Experience Centre (CEC), now providing Australian and New Zealand researchers first access to MGI's cutting-edge DNA, Cell and Spatial Omics (DCS) capabilities. 

The Customer Experience Centre established in 2021 was launched to provide users in Australia and New Zealand (ANZ) unique access to MGI's innovative technology portfolio, including the proprietary DNBSEQ^TM platforms, laboratory automation systems, and bioinformatics appliances.

After two years of continuous commitment to innovation, the CEC has just undergone a significant expansion of capabilities to support research efforts in the region. It proudly stands as the inaugural CEC with DCS Lab products outside of MGI's home market in China.

"We are excited to be able to support the Australian and New Zealand Research Community in accessing and evaluating the DCS facility solution", said Dr Haofei Wang, Manager of the CEC with DCS Lab products in Brisbane. "Scientists will be able to see the solution in operation before implementing it rapidly in their own institutes."

The DCS Lab, powered by the core technologies of DNBSEQ^TM, is a revolutionary program poised to springboard research capabilities for emerging scientific leaders everywhere. This program, distinguished by its seamless integration of three advanced technologies, delivers fundamental discovery technologies in DNA Sequencing, Single Cell Omics, and Spatial Transcriptomics. Designed for operational efficiency, DCS Lab accelerates research timelines by years through a streamlined delivery process. Eliminating integration complexities associated with diverse platforms, it establishes a stable foundation for the swift assimilation of new capabilities. Participants benefit from dedicated support, ensuring optimal functionality of proven technologies, including DNBelab-C4 and DNBelab C-TaiM 4RS single-cell solutions and STOmics Stereo-seq spatial multi-omics technology. DCS Lab can subsequently be tailored based on throughput needs and its exceptional expandability allows for the seamless addition of new capabilities, providing adaptability to evolving research needs. This program not only propels research forward but also grants early access to MGI's latest innovations, positioning research teams at the forefront of technological advancements.

"Our commitment to advancing scientific research in the ANZ region has fuelled the evolution of our Customer Experience Centre." Dr. Bicheng Yang, Director of MGI Australia, highlights the lab's dual role as a Research and Development centre, focusing on innovative application development with regional significance. "We are thrilled to introduce the Customer Experience Centre with DCS capabilities in Australia. This facility represents a significant leap forward in the convergence of DNA, Cell, and Spatial-omics technologies, providing researchers with first-hand access on tools and technologies to drive ground-breaking discoveries."

The Customer Experience Centre in Australia solidifies MGI's position as a leader in genomics innovation, ushering in a new era of scientific exploration and discovery. Positioned as a catalyst for collaborative research endeavours, this facility is primed to drive advancements with far-reaching impacts across diverse fields, encompassing medicine, environmental science, cancer research, agriculture, and beyond.

For access enquiries contact Richard Harrison, richardharrison@mgi-tech.com. +61 42 457 456

About MGI

MGI Tech Co. Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers**, and its multi-omics platforms include genetic sequencing**, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.